A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
This study will investigate the efficacy and safety of MK-4827 in participants with relapsed mantle cell lymphoma (MCL) and in a subset of participants with inactivation of the Ataxia-Telangiectasia Mutated (ATM) gene.
Lymphoma|Mantle-Cell
DRUG: MK-4827
Number of participants who have a complete response (CR) or partial response (PR) during the study, Tumor assessments will be performed every 9 weeks for the first year the participant is on treatment, every 12 weeks in year 2, and every 6 months in year 3 and beyond
Number of Participants with adverse events, From the day of enrollment through 30 days after the last dose of study drug|Time from allocation to disease progression or death from any cause (Progression-free survival), Tumor assessments will be performed every 9 weeks for the first year the participant is on treatment, every 12 weeks in year 2, and every 6 months in year 3 and beyond
This study will investigate the efficacy and safety of MK-4827 in participants with relapsed mantle cell lymphoma (MCL) and in a subset of participants with inactivation of the Ataxia-Telangiectasia Mutated (ATM) gene.